Memo Therapeutics AG’s Post

𝐌&𝐀 𝐢𝐧 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚: 𝐍𝐨𝐭 𝐉𝐮𝐬𝐭 𝐚 𝐓𝐫𝐚𝐧𝐬𝐚𝐜𝐭𝐢𝐨𝐧, 𝐛𝐮𝐭 𝐚 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 1️⃣ Sizeable Capital Biopharma giants are not just sitting on capital; they're on a mountain of it. 🔍 $𝟏.𝟑𝟕 𝐭𝐫𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐬 𝐧𝐨𝐭 𝐣𝐮𝐬𝐭 𝐚 𝐧𝐮𝐦𝐛𝐞𝐫. It's a statement. 2️⃣ Using Firepower But this capital isn't for keeping. It's for spending, wisely. 💡 These funds are the key to unlocking future growth and innovation. 3️⃣ Strategic Moves It's not just about acquiring. It's about strategic transformation. 🚀 Each M&A is a step towards a more robust, innovative future. 💥 Remember, it's not just a deal. It's a pivotal move in shaping healthcare's future. 𝐖𝐡𝐚𝐭'𝐬 𝐲𝐨𝐮𝐫 𝐭𝐚𝐤𝐞 𝐨𝐧 𝐭𝐡𝐞 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐭𝐡𝐞𝐬𝐞 𝐌&𝐀𝐬? P.S. Repost this tip for your network ♻️ Thank you! #oncolyst #EYPredicts #cancer #biopharma #oncology Read More here: https://lnkd.in/dkqCVtN9

Great to see Commit Biologics featured in BioCentury Inc.’s Emerging Company Profile series🚀!   It comes after our CEO, Krishna Polu spoke to BioCentury Inc.'s Danielle Golovin, Ph.D. about Commit Biologics' novel approach to activating the complement pathway. In the piece, Krishna discusses how our bispecific complement engager (BiCE) technology engages C1q to trigger highly selective complement-induced killing of #cancer or #autoimmune cells. You can read more using the link below 👇 #ComplementSystem #ImmuneSystem #BioCentury

Check out this fantastic episode with Commit Biologics which is pioneering a new way to tackle cancer and autoimmune disease.

ATTN #BIO2024: Today at 2:30 pm, our CEO, Bob Linke, gives a company presentation about OSM-0205, our lead product. We look forward to providing an update on our plans for OSM-0205, which is poised to initiate clinical development later this year. OSM-0205 is a preventative treatment to help patients avoid the painful and debilitating effects of chemotherapy-induced peripheral neuropathy (CIPN), common amongst taxane-based chemotherapies, including the leading breast cancer chemotherapy treatment. CIPN affects as many as 80% of these cancer patients and can significantly impact both quality of life and survival. Stop by to see our company presentation or request a meeting with our CEO, Bob Linke through, the Biotechnology Innovation Organization (BIO) One-on-One Partnering™ System: https://lnkd.in/eEDtKaAK #oncology #biotech #investors

Rhythm Biosciences Limited Explore the financial implications of Rhythm Biosciences' advancements in diagnostic solutions for gastric cancer and its potential impact on investors. Read More https://lnkd.in/e3gg_3mK #FinancialMetrics, #diagnosticIndustry, #gastricCancer, #investment, #profitability

Let’s de-risk your drug development journey 🚀 At Physiomics plc, our expert team uses advanced data science and mathematical modelling techniques to predict and enhance therapeutic outcomes with precision. We’re here to help you navigate the complexities of R&D across pre-clinical, translational, and clinical stages. Learn how our proven solutions can guide your decisions from discovery to the clinic: https://lnkd.in/e7rA8RCH #Cancer #DrugDevelopment #CancerDrugs #CancerSimulation #InSilico #QSP #MathematicalModelling #PKPD #MechanisticModelling #Oncology #ClinicalTrials #ResearchandDevelopment #CancerResearch #BioTech #StatisticalModelling #MachineLearning #Pharma #TranslationalModelling #PYC

Shareholder Update Presentation: March 2024 #SNT #Investing #Finance #SyntaraLimited #InvestorWebinar #ASX #myelofibrosis #cinicaltrial #bonemarrowcancer #cancer #biotech #presentation #asxnews

We are thrilled to announce the publication of a 10-day study conducted by Charles River, comparing Kytopen’s Flowfect Tx™ cellular engineering platform with two commercially available electroporation platforms. A key finding in this study was the considerably higher yields of gene-edited, viable cells with the Flowfect Tx™ platform. “We have a GMP-scale manufacturing platform that has already been evaluated for tech transfer and this study further highlights the ease of implementation to develop superior yields of final drug substance", said Kevin Gutshall, Chief Commercial Officer at Kytopen. To access the full press release: https://lnkd.in/gJnfCgMX To access the summary of the study, Making Gains in Non-Viral Engineering of T Cells for Cell Manufacturing, visit https://bit.ly/3ANGxxF  #celltherapy #regenerativemedicine #tcells #cancer #cancerresearch #geneediting #innovation

[#Meet2Win] 📅 May 16-17, 2024 📍 Bordeaux, France   Virginie Carrincazeaux was part of Meet2Win 2024, the European partnering convention entirely dedicated to open innovation in #oncology. Meet2win brought together leading #experts in this field. Creapharm, a Myonex company supports Pharma and Biotech companies developing #cancer therapies with: ➡ #CTSM: decades of exeriences in Clinical Trial Supply management in oncology phase I-III studies ➡ #biobanking: highly-secured storage of the most valuable research biospecimen ➡ #ATMP supply chain: with a strong expertise in ultra-cold chain management, Creapharm handles storage, packaging and logistics of the most innovative therapies, such as CAR-T cells. Thank MATWIN for arranging an event with such a high scientific level.

InduPro, a startup founded by former Merck scientists Scott Lesley, Niyi Fadeyi, and Rob Oslund, has raised $85 million to map and drug protein interactions in cancer and autoimmune disease. One goal is to find new pairs of proteins that can be hit simultaneously for more targeted drugs. Another is to latch onto proteins on different cell surfaces to bring the two cells together. Former Ribon CEO and Flagship and Novartis exec Prakash Raman will lead the startup. Read more in my exclusive story for Endpoints News https://lnkd.in/dm4kV79Y #biotech #startup #seriesA #funding #cancer #cancerdrug #cancertherapy #precisiononcology #immunotherapy #autoimmune #protein #proteinscience